Cardionovum® Begins In Vivo Testing of Its Paclitaxel-Coated RESTORE® Drug-Eluting Balloon (DEB), Designed to Increase Drug-in-Tissue Concentration
7/3/2012 9:41:06 AM
BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH: Cardionovum GmbH announced today that it has initiated in vivo testing of its second drug-eluting balloon (DEB) RESTORE™. The Company is currently marketing a line of CE-marked paclitaxel-coated DEBs for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.